Abstract Purpose: Triple-negative (TN; estrogen receptor, progesterone receptor, and HER-2 negative) cancer and basal-like breast cancer (BLBC) are associated with poor outcome and lack the benefit of targeted therapy. It is widely perceived that BLBC and TN tumors are synonymous and BLBC can be defined using a TN definition without the need for the expression of basal markers. Experimental Design: We have used two well-defined cohorts of breast cancers with a large panel of biomarkers, BRCA1 mutation status, and follow-up data to compare the clinicopathologic and immunohistochemical features of TN tumors expressing one or more of the specific basal markers (CK5/6, CK17, CK14, and epidermal growth factor receptor; BLBC) with those TN tumors that express none of these markers (TN3BKE-).
Breast cancer comprises an extraordinarily diverse group of diseases in terms of presentation, morphology, molecular profile, and response to therapy. Gene expression analysis has identified molecular classes of breast cancer that are biologically and clinically distinct. One of these subgroups, which has attracted significant attention in recent years, is basal-like breast cancer (BLBC; refs. 1 -3) . BLBC is characterized by expression of genes usually found in basal/myoepithelial cells of the normal breast (1, 2) . Using unsupervised hierarchical clustering analysis, BLBC are placed within a cluster of estrogen receptor (ER)-and HER-2-negative tumors and are associated with poor prognosis (1 -3) . Although gene expression profiling is considered the ''gold standard'' method for identification of BLBC, this approach is not currently feasible for large-scale clinical applications or retrospective studies using formalin fixed, paraffin-embedded samples. Therefore, as an alternative, expression of basal/myoepithelial cell proteins identified by immunohistochemical staining has been used as a surrogate of gene expression. However, there is currently no consensus on the optimum immunohistochemical panel to define BLBC and several combinations of basal markers have been proposed. Based on the frequent expression of basal cytokeratins in BLBC and the association between basal cytokeratins and poor prognosis (4) , some studies, including our own, have used basal cytokeratins (e.g., CK5/6, CK17, and CK14) alone to define BLBC (5 -7) regardless of the expression of other markers. The significance of ER-positive/basal cytokeratinpositive tumors is still not known, and most of the BLBC identified by gene expression analysis are characterized by ER and HER-2 negativity (8) . Therefore, it has been perceived that it is more practical and biologically acceptable to restrict identification of BLBC to within the ER-and HER-2-negative group of tumors. In a seminal study of 21 BLBC cases identified by gene expression analysis, an immunohistochemical surrogate of four markers showed a sensitivity of 76% and a specificity of 100% for the identification of these tumors (9) . This immunohistochemical surrogate is based on the positive expression of two basal markers [CK5/6 and/or epidermal growth factor receptor (EGFR)] in tumors negative for both ER and HER-2. This definition is currently considered one of the most pragmatic and widely accepted definitions of BLBC (9 -11) . In addition, some authors have included progesterone receptor (PR) negativity to define BLBC as triple-negative (TN; ER, PR, and HER-2 negative) tumors that express CK5/6 and/or EGFR (10, 12) .
Despite the fact that several studies have shown that not all BLBC are TN (8, 13 -15) and that not all TN cancers have a basal-like phenotype (8, 16) , there is a pervasive misconception that BLBC are composed entirely of TN breast cancers and that all TN tumors are synonymous with BLBC (16 -18) . These misconceptions have led to claims that TN phenotype could be used as a reliable surrogate for BLBC (16) .
From the oncologist's standpoint, TN tumors are undeniably one of the most relevant subgroups of breast cancer given the lack of targeted therapies for this group and their aggressive clinical behavior. ER, PR, and HER-2 are used in routine practice; therefore, TN tumors can be easily identified and often be extracted from existing clinical records. However, it should be emphasized that TN cancers are a more heterogeneous group of breast cancers than BLBC (8) . In fact, gene expression studies have shown that ER-and HER-2-negative tumors clustered into at least two distinct molecular classes: BLBC and the so-called normal breast-like. Furthermore, a recently identified subtype of breast cancers, the claudin-negative cancers, has also been shown to consistently harbor a TN phenotype (19) . Although the latter groups are still poorly characterized, it should be noted that normal breast-like cancers are reported not to respond to neoadjuvant chemotherapy at the same frequency as BLBC and to have a better prognosis compared with BLBC (3, 20) .
We and others have shown that between 50% and 80% of TN tumors express basal markers (8, 10, 12, 21, 22) , identifying a subgroup of tumors that is associated with poor outcome (12, 23, 24) . Although the prognostic value of TN and BLBC is of paramount importance, the significance of BLBC stems not only from its poor prognostic features but also from its distinct molecular and biological characteristics, which has led to increased interest in BLBC as a means of identifying better systemic therapy regimens and novel therapeutic targets for these aggressive tumors. In a previous study, Turner et al. (25) have suggested that tumors expressing more than one basal keratin are more likely to have a dysfunctional BRCA1 pathway. Preclinical models of tumors with dysfunctional BRCA1 have been shown to have an exquisite sensitivity to cross-linking agents and inhibitors of the poly(ADP-ribose) polymerase (26) . Taken together, these findings suggest that the use of basal markers may help reduce the heterogeneity of TN cancers and to identify a more biologically and clinically meaningful subgroup of these tumors. However, the biological significance and the clinical features of TN tumors with and without expression of basal markers are still unclear. Therefore, in this study, we focused on TN invasive breast carcinomas aiming to determine the clinicopathologic and biological differences between TN tumors that express basal markers [CK5/6, CK17, CK14, and EGFR (7, 9, 12, 21) ; BLBC] and those that are negative for these basal markers [TN, 3 basal keratins and EGFR negative (TN3BKE-)] using a well-characterized series of breast cancer (n = 1726) with long-term follow-up and a large panel of biomarkers with relevance to breast cancer.
Furthermore, several studies (27, 28) have shown that basallike keratins are good predictors of BRCA1 mutation status. However, the relative contribution of ER, PR, HER-2, and basal markers, when used alone and in combination, in predicting germ-line BRCA1 status in breast cancer has not been fully studied. To assess this, we used an ethnically restricted cohort of breast cancer cases (n = 292 cases) with known BRCA1 and BRCA2 mutation status.
Materials and Methods
This study was based on a well-characterized series of tumornode-metastasis stage T 1 and T 2 primary operable invasive breast carcinoma cases entered into the Nottingham Tenovus Primary Breast Carcinoma Series between 1987 and 1998 (n = 1,944). Patients were ages <70 years and treated according to the local protocols. Patients' clinical history and tumor characteristics, information on therapy, tumor recurrence, and survival were available and are described in our previous publications (23, 29) . Other histopathologic parameters (pushing margins, tumor lymphoid infiltrate, or presence of comedotype necrosis) were defined elsewhere (30) . Radiologic features of these tumors were reviewed for the present study by a radiologist (A.J.E.) blinded to the results of immunohistochemical analysis.
Translational Relevance
Triple-negative (TN) cancer and basal-like breast cancer (BLBC) are associated with poor outcome and lack the benefit of targeted systemic therapy. It is widely perceived that TN and BLBC tumors are synonymous and BLBC can be defined using a TN definition without the need for the expression of basal markers. Clinical trials based on TN definition of BLBC are currently under way. Conclusions from these trials are likely to be affected by the noise in subtype definition introduced by merely relying on the lack of hormone receptors and HER-2. Few recent studies have addressed this issue and showed differences in the outcome between both tumor subtypes. Our study provided evidence thatTN is a heterogeneous group of tumors. Expression of basal markers identifies a biologically and clinically distinct subgroup of TN tumors, justifying the use of basal markers (inTN tumors) to define BLBC.
Breast cancer tissue microarrays were prepared and immunohistochemically stained as described previously (23, 31) . This study included 54 biomarkers of clinical and biological relevance to breast cancer (Table 1) . Cutoff values for the different biomarkers included in this study were the same as for previously published patient series (23, 29, 32, 33) .
Of all tissue microarray cases informative for ER, PR, and HER-2 (n = 1,726), 282 (16.3%) showed a TN phenotype. Of the 1,277 invasive ductal carcinomas of no special type (34) informative for all these three markers, 232 (18%) of cases were TN and these formed the basis of the current study. Of the 232 TN invasive ductal carcinomas of no special type included in this study, 94% (217) of cases were grade 3, whereas 6% (15) of cases were grade 2 and none were grade 1. At the time of the primary diagnosis, 140 (60%) patients had lymph nodenegative disease, 148 (64%) were negative for vascular invasion, and 112 (52%) patients received Bonadonna-type CMF chemotherapy (none of these patient received anthracycline-based chemotherapy). The patients had a median age of 50 years (range, 25-70 years). For these cases, the median overall survival was 119 months (range, 4-207 months) and the median time of event-free survival was 109 months (range, 3-207 months). Recurrence occurred in 88 (40%) cases, distant metastases occurred in 77 (34%) cases, 77 (34%) patients died from breast cancer, 19 died from other causes or lost to follow-up, and 123 (54%) patients were alive at the end of follow-up. Of these 232 TN cases, 165 (71%) tumors were positive for the basal markers (CK5/6 and/or CK17 and/or CK14 and/or EGFR). These tumors were defined as BLBC (7, 9, 12, 21) . The remaining TN cases (67 cases, 29%) were negative for all of these four basal markers and defined as TN breast cancer negative for the three basal keratins and EGFR (TN3BKE-). This study was approved by Nottingham Research Ethics Committee 2 under the title of Development of a Molecular Genetic Classification of Breast Cancer.
To assess the prevalence of BRCA1 and BRCA2 germ-line mutation status according to BLBC and TN3BKE-phenotype, we analyzed an independent cohort of tumors comprising 292 consecutive cases of Ashkenazi Jewish women ages V65 years diagnosed with a first primary, nonmetastatic, invasive breast cancer between January 1, 1980 and November 1, 1995 at the Sir Mortimer B. Davis-Jewish General Hospital. This is an ethnically restricted single hospital-based retrospective cohort that has been described in detail in previous publications (6, 35) . This cohort (Montreal cohort) has been used previously to determine the associations between expression of ER, PR, HER-2, CK5/6, and EGFR (CK14 and CK17 were not available) and the mutation status of both BRCA1 and BRCA2 as well as patients' outcome (6) . For these analyses, 278 tumors were available for analysis (10 tumors from patients harboring BRCA2 germ-line mutations were excluded from this analysis because of the small sample size). (36) . Multivariate analysis was done by Cox's proportional hazards analysis. P < 0.05 (two sided) was considered significant. However, with multiple statistical comparisons, P < 0.01 was considered significant.
Results
Clinicopathologic features of BLBC and TN3BKE- Table 2 shows the main clinicopathologic features of both BLBC and TN3BKE-. There was no significant difference between BLBC and TN3BKE-regarding patients' age, menopausal status, bilaterality, type of surgery, primary tumor size, tumor histologic grade, tubule formation, presence of vascular invasion, pushing margins, tumor lymphoid infiltrate, or presence of comedo-type necrosis. When compared with TN3BKE-tumors, BLBC showed an association with lower prevalence of lymph node metastasis at diagnosis (P = 0.01) and presence of marked cellular pleomorphism.
No statistically significant differences in the mammographic features were detected between BLBC and TN3BKE-tumors. Both groups showed a high rate of ill-defined mass (59% and 56% for BLBC and TN3BKE-, respectively) and calcification and low rates of spiculation (14% and 13%).
Immunophenotypic features of BLBC and TN3BKE-
Cell cycle regulators and cell proliferation. A panel of eight cell cycle-associated proteins (p53, Rb, p21, p27, p16, cyclin D, cyclin E, and BRCA1) was analyzed. A significant association was found between BLBC and elevated levels of both p53 and p16 (P = 0.006 and 0.012, respectively). When compared with TN3BKE-tumors, BLBC showed a positive association with the nuclear expression of c-Myc (P = 0.006) and high mitotic index as defined by phospho-histone 3 (P = 0.001), indicating an association between BLBC and a growth fraction.
Luminal epithelial cell markers and other biomarkers. BLBC was associated with more frequent expression of luminal CK19 (P = 0.005). Although BLBC showed lower levels of expression of CK18, this association was not significant (P = 0.1). BLBC showed a positive association with the expression of neuroendocrine differentiation markers [chromogranin A (P = 0.009) or combined chromogranin A and synaptophysin (P = 0.004)], hypoxia-associated factor (CA9; P = 0.006), FHIT protein (P = 0.004), and ER-h1 (P = 0.008). BLBC showed an association of borderline significance with the expression of P-cadherin (P = 0.02).
Immunologic markers. BLBC showed a positive association with the expression of MHC class I polypeptide-related sequence A (P = 0.006) and HC10 (P = 0.004). BLBC also showed an association of borderline significance with the expression of MUC2 (P = 0.03).
BRCA status. The Montreal series was used to assess the mutation status of BRCA1 in the different tumor subgroups. Of the 278 informative cases in this series, 77 (27.7%) cases were ER and HER-2 negative, and of these, 67 had data on CK5 and EGFR. Forty-three (64.2%) were positive for CK5 and/or EGFR. Our results showed that, as expected (27, 28) , both BLBC and TN phenotypes are highly predictive of a germ-line BRCA1 mutation (Table 3A) . However, when we restricted our analysis to ER-and HER-2-negative tumors (some PR data were missing, precluding a direct comparison with TN tumors), germ-line BRCA1 mutations were significantly more likely to be found in ER-and HER-2-negative breast tumors expressing CK5/6 and/or EGFR (BLBC) than in tumors that did not express these markers (TN1BKE-; odds ratio, 13.04; 95% confidence interval, 1.60-106; P = 0.003; Table 3B ). Within the ER/HER-2-negative group, only 4.3% of CK5/6 and EGFRnegative tumors carried a BRCA1 mutation compared with 37.2% of CK5/6 and/or EGFR-positive tumors that carried a BRCA1 mutation. This suggests that if the aim is to identify women who may be eligible for BRCA1 genetics testing, then CK5/6 and EGFR will be an important adjunct to routine immunohistochemistry.
Patients' outcome
Patterns of metastatic dissemination. Distant metastases developed in 54 (37%) cases of BLBC compared with 16 (26%) cases in TN3BKE-tumors after 10 years of follow-up. Metastatic BLBC tumors showed a unique pattern of distant metastasis with frequent metastasis to two or more sites (disseminated disease) compared with TN3BKE-tumors that showed frequent metastasis to single distant metastasis sites. Of the cases with known site of distant metastasis, BLBC showed more frequent metastasis to brain and lung but less frequently metastasize to other lymph node groups than TN3BKE-tumors. However, no significant difference was noted in case of bone or liver metastases in BLBC compared with TN3BKE-tumors in order (Table 4) .
Survival analyses. When compared with TN3BKE-, BLBC showed an association with both shorter breast cancerspecific survival (BCSS) and shorter disease-free survival (DFS) after 5 years of follow-up (log rank = 4.2; P = 0.04 and log rank = 4.4; P = 0.03 for BCSS and DFS, respectively). At the end of the follow-up period (207 months), BLBC was associated with shorter DFS (log rank = 5.8; P = 0.01) and showed a nonsignificant association with shorter BCSS (log rank = 3.5; P = 0.06; Fig. 1A and B) . When we analyzed the association between well-established prognostic factors in breast cancer and outcome in both tumor groups, a difference was found in which vascular invasion was of prognostic value in BLBC, whereas tumor size had prognostic value in TN3BKE-tumors. Multivariate analyses including these prognostic variables showed that in BLBC vascular invasion is the only independent predictor of DFS, whereas in the TN3BKE-group the independent prognostic factors were lymph node stage (for both BCSS and DFS) and tumor size (for BCSS).
Exploratory analysis of the interactions between chemotherapy (patients who received or did not receive Bonadonna CMF chemotherapy) and BLBC and TN3BKE-groups revealed that patients with BLBC tumors who did not receive chemotherapy had a shorter DFS than those with TN3BKE-tumors. On the other hand, in the group who received chemotherapy, this difference was no longer present (Table 5) . No difference in the association between both tumor groups and BCSS in the two chemotherapy treatment subgroups was observed.
The association between BLBC and poor outcome, when compared with the association between TN and poor outcome, was confirmed in the Montreal cohort of tumors. At 10 years of follow-up, tumors expressing one or two basal markers (CK5 and/or EGFR) showed an 18.9% decrease in BCSS compared with tumors that did not express either of these two basal markers (75.5% versus 56.6%; P = 0.0002), whereas TN tumors showed no such significant association (BCSS of 69.4% for TN tumors compared with 75.3% for non-TN tumors; P = 0.105). Among ER-and HER-2-negative tumors (n = 67), there was no significant difference in survival between those expressing basal markers (n = 43) and those that did not express these markers (n = 24; P = 0.16).
Discussion
In this study, we have used a well-characterized series of breast cancer to assess the pathobiological and clinical features of TN tumors with (BLBC) and without (TN3BKE-) specific basal markers expression. We used a large panel of biomarkers with relevance to breast cancer and an updated comprehensive outcome data. In the current study, we have restricted our analysis to invasive ductal carcinoma of no special type to avoid any confounding effect of special types of invasive breast cancer such as lobular, medullary, salivary gland-like, and mixed carcinomas. In this series, 71% of TN tumors expressed one or more of the basal markers (BLBC). Our results showed that the cardinal morphologic features of BLBC are not different from those of TN3BKE-tumors. However, biological differences between both tumor groups exist and can therefore justify the use of basal markers in TN tumors to define BLBC.
Previous studies have shown that many of the genes expressed by BLBC are involved in cellular proliferation (37) . BLBC consistently display a high proliferative profile as defined by gene signatures (38) and are overrepresented among the so-called interval breast cancers (e.g., cancers arising between annual mammograms; ref. 39) , which support the idea of BLBC being a rapidly growing/proliferating tumor. Our results support these previous studies and showed a difference in the expression of cell cycle regulators and cell proliferation markers between BLBC and TN3BKE-tumors. The mechanism of cell cycle regulators and cell proliferation appeared to be different between both tumor groups, with p53 and p16 proteins having discriminating roles being expressed at high levels by BLBC. Although we did not find an association between the two TN Our results also showed that BLBC are different from TN3BKE-tumors in several other aspects. BLBC showed frequent expression of (a) the hypoxia-associated factor (CA9), (b) the tumor suppressors FHIT protein and p53, and (c) neuroendocrine markers and showed difference in the expression of biomarkers involved in the immunologic portrait of tumors, such as Lewis blood group antigen and anti-MHC/ anti-HLA class I antibodies.
In contrast to previous studies that showed an association between BLBC and negativity for luminal cytokeratin expression (41), we report more frequent expression of luminal cytokeratin (CK19) in BLBC when compared with TN3BKE-tumors. This capacity to coexpress basal and luminal cytokeratins could have biological and clinical implications, suggesting that BLBC may either have features of dual-lineage differentiation or a more stem-like phenotype than TN3BKE-tumors, which may result in their increased aggressiveness. Consistent with our findings, it has recently been reported that BLBC also differs from TN3BKE-tumors in the expression of CD44 + / CD24 -; the proposed population of breast cancer cells enriched for cells with stem cell properties (42) and in the expression of genes associated with abrogated response to cellular stress (43) . Similar to our previous observations (41), we did not find a difference between BLBC and TN3BKE-tumors regarding the expression of myoepithelial markers included in this study.
Breast cancers arising in carriers of germ-line BRCA1 mutations are predominately of basal-like type, suggesting that BRCA1 dysfunction may play a role in the pathogenesis of sporadic basal-like cancers (25, 27) . Some previous studies have reported that BRCA1 carrier status can be accurately predicted using basal marker expression (basal cytokeratins and EGFR) alone (6, 27) or combined with ER negativity and morphology (28) . Other authors have considered that the basal-like phenotype may be due to BRCA1 pathway dysfunction (25, 44, 45) . We showed, in the Montreal series, that BRCA1 mutations are more likely to be found in TN tumors expressing CK5/6 and/or EGFR compared with TN tumors that do not express these markers. Also, consistent with a previous report (46) , which showed that lack of ER expression is the In this series, the definition of tumor groups was defined as follows: (a) Tumors are BLBC when ER is negative, PR is negative, and HER-2 is negative and CK5/6, CK14, CK17, or EGFR is positive (even if the one is missing). (b) Tumors are TN3BKE-when ER is negative, PR is negative, and HER-2 is negative and CK5/6, CK14, CK17, and EGFR are negative. It is missing otherwise.
strongest predictor of BRCA1 germ-line mutations (46), our results showed an association between TN phenotype and BRCA1 carrier status when compared with non-TN tumor. A previous study suggested that ER, PR, and HER-2 are better predictors of BRCA1 status than are basal keratins (47) . In contrast with that study (47) , when our analysis was restricted to the TN group, the association between BLBC and BRCA1 status was maintained (Table 3B) , emphasizing the association between basal marker expression and BRCA1 status even within the TN tumors. BLBC showed a distinct pattern of metastasis when compared with TN3BKE-tumors with frequent metastasis to brain and lung and less to other lymph node groups (m 2 = 11.1, df = 4, P = 0.026). Moreover, although in our series BLBC was not different to TN3BKE-tumors regarding grade, size, or vascular invasion and was less frequently associated with lymph node metastasis, which is one of the most powerful poor prognostic factors in breast cancer, BLBC showed an association with poorer outcome, although this was not statistically confirmed in the perhaps underpowered Montreal cohort. This may reflect the aggressive clinical behavior of these tumors from the onset of tumor development, which cannot be explained by a late presentation at a more advanced stage reflected in more quiescent tumor profiles. Although the number of cases in both series may not be sufficiently powered to comment on each class separately, our findings support the contention that there are important clinical and biological differences between BLBC and TN3BKE-tumors. In addition, the value of some well-established prognostic variable such as vascular invasion and tumor size in predicting outcome was different in both tumor groups. Although some studies have reported that BLBC do not respond well to anthracycline-based chemotherapy (5, 12, 22, 48), here we showed that patients with BLBC who received adjuvant Bonadonna CMF chemotherapy appear to respond better than patients with TN3BKE-tumors. However, it is important to mention that these results are not necessarily conflicting because the chemotherapy regimens received were different: none of our patients included in this analysis received anthracycline-based chemotherapy. In addition, our results show that BLBC patients who received CMF chemotherapy fared better than BLBC patients who did not receive chemotherapy. The response to CMF chemotherapy was more obvious in BLBC than that in the TN3BKE-tumors.
In this study, we have employed a definition for BLBC that is 100% specific and has at least 76% sensitivity. It could be argued that by the inclusion of additional markers of basal-like phenotype, such as aB-crystallin, nerve growth factor receptor, nestin, and fascin (49), a substantially higher number of TN3BKE-cancers would be considered of basal-like phenotype. It should be noted, however, that by employing the combination of four basal markers, we have shown that 71% of TN cancers are of basal-like phenotype. This is in almost perfect agreement with the study of TN breast cancers by expression profiling recently done by Bertucci et al. (8) , who showed that 71.5% of TN cancers display a basal-like expression array profile. Further studies comparing results of expression array analysis and immunohistochemical panels are warranted to define an optimal immunohistochemical surrogate for BLBC. One should also take into account the fact that alternative ways to subclassify TN tumors into biological, predictive, and prognostic subgroups have been suggested.
In conclusion, here we showed that recognition of basal marker (basal cytokeratins and EGFR) positivity within the group of TN (ER, PR, and HER-2 negative) tumors could 
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